New insights into halting type 1 diabetes

Overview of attention for article published in The Lancet Diabetes & Endocrinology, June 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

news: 3 news outlets

twitter: 10 X users

Readers on

mendeley: 6 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Cancer drug may slow course of type-1 diabetes

Pediatric News , 19 Jul 2021

NEW YORK (Reuters) - The tyrosine-kinase inhibitor imatinib used to treat chronic myeloid leukemia and other cancers may help…

Cancer Drug May Slow Course of Type 1 Diabetes

Medscape, 19 Jul 2021

NEW YORK (Reuters Health) - The tyrosine-kinase inhibitor imatinib used to treat chronic myeloid leukemia and other cancers may…

Imatinib could slow beta-cell decline in early type 1 diabetes

medwireNews, 07 Jul 2021

medwireNews: A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.